| Common Brands | Avapritinib |
|---|---|
|
Drug Class |
Tyrosine kinase inhibitor |
|
Controlled Substance Classification |
Not a controlled medication |
|
Generic Status |
No Lower-cost generic available |
|
Availability |
Prescription only |
Avapritinib is a targeted therapy drug primarily intended for use with certain types of cancer. It is used most predominantly in the treatment of gastrointestinal stromal tumors (GIST) and other cancers caused by a specific genetic mutation. This drug is classified as a kinase inhibitor.
This means it works by blocking specific enzymes, known as kinases, which promote the growth and spread of cancer cells. Avapritinib is generally thought to be a breakthrough therapy for the advanced GIST or other cancers from mutations in the KIT and PDGFRA genes.
Developed by the biotech firm Blueprint Medicines and approved by the U.S. Food and Drug Administration for medical use in 2020, avapritinib is designed to target selected mutations that it matches better than traditional cancer treatments
Avapritinib is administered orally, usually once per day, as a tablet. The actual dosage and treatment regimen will depend on the diagnosed condition and patient-specific factors that include their health status and response to the treatment.
Administration: Tablets should be swallowed whole with water. They should not be crushed or split and not be chewed.
Food Interactions Avapritinib may be administered with or without food, but the timing in relation to meals should be consistent.
If a dose is missed it should be taken as soon as possible, except if the next dose falls within 12 hours. In such cases the missed dose is skipped and the schedule of regular doses is resumed.
Avapritinib works through inhibition of the action of abnormal or mutant tyrosine kinases. Tyrosine kinases are enzymes that, under normal conditions, help regulate cell growth and division. In mutated forms, though, they cause uncontrolled cell growth, which can result in cancer.
Specifically, it targets mutated KIT and PDGFRA receptors – a common mutation seen in GISTs as well as most other related cancers. The function of the mutated kinases is blocked by Avapritinib, preventing the cancer cells from receiving the necessary signals to proliferate and stay alive.
Selective inhibition could potentially help to slow the growth of the tumor, reduce the size of tumors that have already developed, and may also bring improvements in symptoms for patients with advanced or metastatic cancer.
Like all medicines, Avapritinib causes side effects. Common and serious side effects are as follows:
Common Side Effects :
Nausea and vomiting
Fatigue
Swelling (edema)
Decreased appetite
Skin rashes or reactions
Serious Side Effects:
CNS Effects: Avapritinib can result in altered mental status, like confusion, dizziness, or fainting.
Bleeding Problems: There is a likelihood of Bleeding or bruising due to the drug.
Cardiac Issues: Avapritinib may lead to heart problems; arrhythmia is one of them (irregular heartbeat).
Liver Toxicity: There may be an increase in liver enzymes, indicating potential liver damage.
Before starting Avapritinib, there are several important considerations:
Risk of Bleeding: Patients should be constantly monitored for signs of bleeding, which may include unusual bruising, blood in the urine or stool, or prolonged bleeding from cuts.
QT Prolongation: Avapritinib can cause QT interval prolongation, which is a type of abnormal heart rhythm problem, making it pose a serious threat for cardiac events. Periodic ECG can be required to monitor the cardiac health of patients.
Liver and Kidney Function: Avapritinib may affect liver and kidney function, requiring periodic tests to monitor organ health.
Patients should also disclose any pre-existing health conditions, medications, or allergies to their healthcare provider prior to starting treatment.
The dose of Avapritinib administrated depends on the state of a patient and his tolerance to the drug:
For GIST: For treatment of GIST, the standard dose is 300 mg taken once daily. Dosage could be changed according to the side effects or response of the patient.
For other indications: Dosage for another type of cancer can vary; therefore, treatment regimens should be established by a healthcare provider.
Dosage Adjustments: If there are serious adverse effects or changes in the condition of the patient, the doses may need to be decreased or even withdrawn until the side effects are resolved.
Avapritinib is a prescription-only medication. This means it can only be obtained with a valid prescription from a licensed healthcare provider.
Before prescribing Avapritinib, a doctor will evaluate the patient’s medical history, perform diagnostic tests, and determine whether Avapritinib is the appropriate treatment option based on the patient’s specific cancer type and genetic profile.
Patients may require genetic testing to confirm the KIT or PDGFRA mutation responsible for their cancer, before starting Avapritinib treatment.
Answer: Avapritinib is a targeted therapy used primarily to treat certain types of cancer, particularly gastrointestinal stromal tumors (GISTs) with specific mutations in the KIT gene.
Answer: Avapritinib works as a selective inhibitor of the KIT and PDGFRA receptors. It blocks the abnormal signals that promote cancer cell growth and division.
Answer: Avapritinib is primarily approved for the treatment of GISTs, especially those with the PDGFRA D842V mutation. It is also researched for potential use in other cancers with specific mutations.
Answer: The recommended dosage can vary depending on the specific condition being treated. The standard dose for GIST patients is usually 300 mg taken once daily, but it should always be prescribed by a healthcare professional.
Answer: Avapritinib is administered orally in the form of capsules and should be taken with water, preferably at the same time each day.
Answer: Common side effects include nausea, vomiting, fatigue, edema, and increased liver enzymes. Monitoring for these effects is important during treatment.
Answer: Some medications can interact with Avapritinib. Patients should inform their healthcare provider about all medications and supplements they are taking to avoid potential interactions.
Answer: Avapritinib may cause harm to a developing fetus. It is recommended that women avoid pregnancy during treatment, and breastfeeding is generally not advised due to potential risks to the infant.
Answer: The duration of treatment varies based on the individual’s response and tolerance to the drug. It continues until disease progression or unacceptable side effects occur.
Answer: If a dose is missed, it should be taken as soon as possible unless it’s close to the time for the next dose. In that case, the missed dose should be skipped. Patients should not double the dose.
Answer: Regular blood tests, including liver function tests and complete blood counts, are typically recommended to monitor for side effects and the effectiveness of treatment.
Answer: Clinical trials have shown that Avapritinib is effective in treating GISTs with the PDGFRA D842V mutation, leading to significant improvement in progression-free survival.
Answer: The combination of Avapritinib with other therapies depends on the specific cancer type and treatment plan. Patients should discuss potential combinations with their oncologist.
Answer: Contraindications include known hypersensitivity to Avapritinib or its components. Patients with a history of severe liver disease should use it cautiously.
Answer: Avapritinib should be stored at room temperature, away from moisture and heat, and kept out of reach of children.
Answer: Serious side effects may include signs of liver problems (like jaundice, dark urine), severe allergic reactions (rash, itching, swelling), and cardiovascular issues (chest pain, shortness of breath). Patients should contact their healthcare provider immediately if they experience these symptoms.
Answer: Avapritinib has been approved in several countries, including the United States and European nations, but availability may vary by region. Patients should consult local regulations for access.
Answer: Patients should check with their insurance provider regarding coverage for Avapritinib. Prior authorization may be required, and financial assistance programs may be available through the manufacturer.
Answer: Various clinical trials are occurring to assess Avapritinib’s effectiveness in other cancers and treatment regimens. Interested patients should consult their oncologist for enrollment opportunities.
Answer: Comprehensive information is available from reputable sources such as the official drug manufacturer’s website, the FDA, and medical literature. Patients can also consult their healthcare provider for personalized information.
Seborrheic dermatitis is a widespread chronic inflammatory skin disorder that primarily affects the head, scalp, and upper trunk, which are areas rich in sebaceous glands.
For a considerable time, both scientists and medical experts have been fascinated by the connection between the gastrointestinal tract and the brain. The gut-brain axis
Food intolerances are becoming more widely acknowledged as serious health issues impacting people all over the world. In contrast to food allergies, which are immune
